Volume not number of metastases: Gamma Knife radiosurgery management of intracranial lesions from an Australian perspective.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
04 2019
Historique:
received: 11 09 2018
revised: 31 10 2018
accepted: 17 12 2018
entrez: 3 4 2019
pubmed: 3 4 2019
medline: 6 2 2020
Statut: ppublish

Résumé

To assess the response of the first cohort of patients treated with Gamma Knife radiosurgery in Australia. A prospectively collected cohort of 180 patients with intracranial metastases from different primaries was treated between August 2010 and July 2017. Survival was calculated using the Kaplan-Meier's method. Cox regression was used for multivariate analysis. Currently 141 patients (78.3%) have died of their disease. The median survival for the group as a whole was 9.2 months, with observed differences resulting from the volume of tumor burden (11.4 months for volumes <3.2 cm Results from the first Gamma Knife radiosurgery center in Australia showed that the treatment is feasible and effective, consistent with the international experience. For patients with larger numbers of intracranial metastases, the total volume of the intracranial burden may be of more significance in predicting outcomes. While there appeared to be a difference in survival by histologic origin, this could be related to concurrent systemic immunotherapy available for certain tumors.

Sections du résumé

BACKGROUND AND PURPOSE
To assess the response of the first cohort of patients treated with Gamma Knife radiosurgery in Australia.
MATERIALS AND METHODS
A prospectively collected cohort of 180 patients with intracranial metastases from different primaries was treated between August 2010 and July 2017. Survival was calculated using the Kaplan-Meier's method. Cox regression was used for multivariate analysis.
RESULTS
Currently 141 patients (78.3%) have died of their disease. The median survival for the group as a whole was 9.2 months, with observed differences resulting from the volume of tumor burden (11.4 months for volumes <3.2 cm
CONCLUSION
Results from the first Gamma Knife radiosurgery center in Australia showed that the treatment is feasible and effective, consistent with the international experience. For patients with larger numbers of intracranial metastases, the total volume of the intracranial burden may be of more significance in predicting outcomes. While there appeared to be a difference in survival by histologic origin, this could be related to concurrent systemic immunotherapy available for certain tumors.

Identifiants

pubmed: 30935580
pii: S0167-8140(18)33657-0
doi: 10.1016/j.radonc.2018.12.018
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-49

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Michael A Izard (MA)

Department of Radiation Oncology, Macquarie University Hospital Sydney, Australia; GenesisCare P/L, Alexandria, Australia; Faculty of Health Sciences, University of Sydney, Australia. Electronic address: michael.izard@genesiscare.com.

Vaughan Moutrie (V)

Department of Radiation Oncology, Macquarie University Hospital Sydney, Australia; GenesisCare P/L, Alexandria, Australia.

Jeffrey M Rogers (JM)

Faculty of Health Sciences, University of Sydney, Australia; Macquarie Neurosurgery, Macquarie University Hospital, Sydney, Australia.

Ken Beath (K)

Department of Mathematics and Statistics, Macquarie University, Australia.

Michael Grace (M)

Department of Radiation Oncology, Macquarie University Hospital Sydney, Australia; GenesisCare P/L, Alexandria, Australia.

Bianca Karle (B)

Department of Radiation Oncology, Macquarie University Hospital Sydney, Australia; GenesisCare P/L, Alexandria, Australia.

Annie Ho (A)

Department of Radiation Oncology, Macquarie University Hospital Sydney, Australia; GenesisCare P/L, Alexandria, Australia.

John W Fuller (JW)

Macquarie Neurosurgery, Macquarie University Hospital, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH